Kidney cancer research: Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma, presented by Vincent Wenxin Xu, MD at ASCO #GU2 1 abstract 342
In this study, we try to find a new biomarker for kidney cancer or renal cell carcinoma. Most patients who have kidney cancer present with localized disease that's amenable to surgery. Nonetheless, about a third of those patients will have disease recurrence after surgery, and we currently don't have any blood test that can identify which patients are at the highest risk of recurrence. Kidney injury molecule one is also called Kim one, and it's a protein that's over expressed in kidney cancers and circulates in the blood we studied. Whether plasma Kim one levels can predict outcomes in patients with localized kidney cancer. After an effectively surgeries, we use samples from 418 of these patients, and we measured Kim won in the blood after surgery to see if it was associated with disease free survival or overall survival. We found that higher levels of Kim one were associated with worse disease. Free survival in all patients, even after adjusting for all, are known clinical risk factors, and that patients with the 25th percentile highest rate of KIM one were almost twice as likely to have tumor recurrence at any given time. Compared to patients at the lowest 75th percentile of Kim won. So in conclusion, we show in this study that plasma came. One is a potential new blood test for measuring microscopic kidney cancer for prognosticating disease, free survival and overall survival after surgery, and that it may have used in being able to better identify which patients have the highest risk after kidney cancer surgery.
